Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article
CD38 as Surrogate Marker for HIV Infection in Antiretroviral Naive and Antiretroviral Experienced Patients in Kenya
Njuguna AN1*, Juma KK2, Waihenya RK3, Mpoke S4, Mbuchi M5, Muthami L6, Mathaai R7, Otieno P4 and Nyakundi P4
1Institute of Tropical Medicine and Infectious Diseases, Jomo Kenyatta University of Agriculture and Technology, P.O. Box 62000-00200, Nairobi, Kenya
2Department of Biochemistry and Biotechnology, Kenyatta University, , P.O Box 43844-00100, Nairobi, Kenya
3Department of Zoology, Jomo Kenyatta University of Agriculture and Technology, P.O. Box 62000-00200, Nairobi, Kenya
4Kenya Medical Research Institute, Center for Biotechnology Research and Development, Kenya
5Kenya Medical Research Institute, Center for Clinical Research, kenya
6Kenya Medical Research Institute, Center for Public Health and Research, P.O. Box 54840 - 00200, Nairobi, Kenya
7Department of Biochemistry, University of Nairobi, P.O. Box 30197, G.P.O, Nairobi, Kenya
- *Corresponding Author:
- Adele Nyambura Njuguna
Institute of Tropical Medicine and Infectious Diseases
Jomo Kenyatta University of Science and Technology
P.O. Box 51791 00200,Nairobi, Kenya
Tel: 2540725502005
E-mail: njugunaadele@yahoo.com
Received date: May 19, 2016; Accepted date: June 13, 2016; Published date: June 17, 2016
Citation: Njuguna AN, Juma KK, Waihenya RK, Mpoke S, Mbuchi M, et al. (2016) CD38 as Surrogate Marker for HIV Infection in Antiretroviral Naive and Antiretroviral Experienced Patients in Kenya. Adv Mol Diag 1:107. doi:10.4172/amd.1000107
Copyright: © 2016 Njuguna AN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction H2O in any medium, provided the original author and source are credited.
Abstract
Human Immunodeficiency Virus (HIV) patient management continues to be a challenge all over the world. CD4 absolute counts and viral load are the gold standard tools for monitoring of HIV-1 disease. However, the use of CD4 counts cannot be used solely to determine the overall status of immune system. It requires the additional measurement of viral load. Determination of viral load is also expensive in many places that are limited with resources. Therefore, there is need for identification of other markers for management of HIV. CD38 is one such candidate marker. The main the correlation between CD38 antibody binding capacity (ABC) and viral load. A a negative correlation was established for participants not on drugs, whereas a positive correlation was exhibited between CD4 and viral load for group on drugs. There was a significant correlation between CD38 ABC and viral load. CD38 levels for the group not on drugs was elevated the same way viral load was, whereas for the group on drugs CD38 levels were lowered the same way as viral load. There was no significant correlation between ages with the outcome from the two groups. Quantification of CD38 may therefore be an affordable test that can serve as an extra tool in HIV-1 management. However, more studies are required to justify the use of CD38 as a surrogate marker for HIV patients on ART.
